Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Fate Therapeutics (NASDAQ:FATE – Free Report) had its target price trimmed by Wells Fargo & Company from $5.00 to $4.00 in a ...

As the U.S. stock market faces a turbulent period with major indices like the Dow Jones and S&P 500 on track for their worst week in two years, concerns about tariffs and economic health continue to ...

Stevanato's 2024 revenue hits €1.1B, driven by biopharma growth! Discover how facility expansions & rising demand are transforming their market impact.

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a report issued on Friday. The brokerage set a “sell” rating on the stock. Several other brokerages have ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (the "Company"), a biopharmaceutical company dedicated to ...

Benitec Biopharma Inc.’s BNTC share price has surged by 11.39%, which has investors questioning if this is right time to sell ...

which are available on the SEC’s website at www.sec.gov. Contacts AEON Biopharma NewsMORE Related Stocks ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives ...

Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE ... the Company’s Board of Directors approved a 1-for-72 reverse stock split (the “Reverse Stock Split”) of the Company ...